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Abstract
Background: Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are an important new class of anti-HIV-1 agents.
ALLINIs bind at the IN catalytic core domain (CCD) dimer interface occupying the principal binding pocket of its
cellular cofactor LEDGF/p75. Consequently, ALLINIs inhibit HIV-1 IN interaction with LEDGF/p75 as well as promote
aberrant IN multimerization. Selection of viral strains emerging under the inhibitor pressure has revealed mutations
at the IN dimer interface near the inhibitor binding site.
Results: We have investigated the effects of one of the most prevalent substitutions, H171T IN, selected under
increasing pressure of ALLINI BI-D. Virus containing the H171T IN substitution exhibited an ~68-fold resistance to BI-D
treatment in infected cells. These results correlated with ~84-fold reduced affinity for BI-D binding to recombinant
H171T IN CCD protein compared to its wild type (WT) counterpart. However, the H171T IN substitution only modestly
affected IN-LEDGF/p75 binding and allowed HIV-1 containing this substitution to replicate at near WT levels. The x-ray
crystal structures of BI-D binding to WT and H171T IN CCD dimers coupled with binding free energy calculations
revealed the importance of the Nδ- protonated imidazole group of His171 for hydrogen bonding to the BI-D
tert-butoxy ether oxygen and establishing electrostatic interactions with the inhibitor carboxylic acid, whereas
these interactions were compromised upon substitution to Thr171.
Conclusions: Our findings reveal a distinct mechanism of resistance for the H171T IN mutation to ALLINI BI-D
and indicate a previously undescribed role of the His171 side chain for binding the inhibitor.
Keywords: HIV-1 integrase, Allosteric inhibitors, Aberrant multimerization, Drug resistance
Background
Rapid evolution of HIV-1 phenotypes conferring resistance
to current antiretroviral therapies is a major clinical prob-
lem. The multifunctional nature of HIV-1 integrase (IN)
provides attractive and unexploited targets for developing
complementary antiretroviral compounds to enhance the
treatment options for HIV-1 infected patients. During the
early stage of HIV-1 replication, IN mediates integration
of the reverse transcribed viral genome into human chro-
matin. This activity proceeds in two steps with the first
step, termed 3’ processing, occurring when IN cleaves a
GT dinucleotide from the 3’ ends of the viral DNA. The
second step, a transesterification reaction termed strand
transfer, inserts the processed viral DNA ends into host
chromosomal DNA [1]. Three clinically approved anti-
retroviral drugs raltegravir (RAL), elvitegravir (EVG) and
dolutegravir (DTG) inhibit IN strand transfer activity and
are collectively referred to as IN strand transfer inhibitors
or INSTIs [2]. Importantly, HIV-1 mutations that confer
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fied in patients [3-5]. While the second generation INSTI,
DTG, appears to exhibit a higher genetic barrier to resist-
ance, substitutions in IN that confer low-level resistance
to DTG have been identified [6].
IN catalytic activities depend on the correct assembly
of the stable synaptic complex (SSC) or intasome, where
individual IN subunits engage the viral DNA ends to
form the fully functional IN tetramer [7]. Each of the
three IN domains, the N-terminal domain (NTD), the
catalytic core domain (CCD) and the C-terminal do-
main (CTD), contribute to the assembly of the SSC
through protein-protein and protein-DNA interactions
[8-12]. Unliganded IN subunits exhibit highly dynamic
interplay with the inhibition of this exchange through
the stabilization of subunit-subunit interactions prior
to their binding to viral DNA results in the loss of
enzymatic function [11,13]. Initial studies with the
small molecule inhibitor tetra-acetylated-chicoric acid
have shown that the inhibitor binds at the IN dimer
interface and promotes the incorrect multimerization
of IN, which in turn compromises IN catalytic activity
in vitro [14]. These findings have provided important
proof-of-concept for a new mechanism for inhibition
of IN activity through the modulation of its multimeric
state.
Integration in infected cells is significantly enhanced
by the cellular chromatin associated protein LEDGF/p75
which acts as a bimodal tether to link the lentiviral pre-
integration complex to active genes [15-20]. LEDGF/p75
association with chromatin is mediated through its
N-terminal segment containing the PWWP domain,
which selectively recognizes the H3K36me3 histone
mark as well as non-specifically engages nucleosomal
DNA [21-23]. LEDGF/p75 also binds the IN tetramer
through its C-terminal integrase binding domain (IBD)
by inserting a small loop into a V-shaped cavity located
at the HIV-1 IN CCD dimer interface [20,24-26].
LEDGF/p75 Asp366 establishes a pair of hydrogen
bonds with IN Glu170 and His171 backbone amides,
whereas LEDGF/p75 Ile365 and Leu368 engage in
hydrophobic interactions with both IN subunits [20,24].
In addition, the LEDGF/IBD α-helix 4 forms electrostatic
interactions with α-helix 1 of the IN NTD [26]. Antagon-
ism of HIV-1 IN interaction with LEDGF/p75 through
knockout (KO) of the cellular Psip1 gene, which encodes
for LEDGF/p75 protein, resulted in marked decrease of
HIV-1 infectivity [18,27,28]. Additionally, overexpression
of the LEDGF/IBD, which is capable of both competing
with endogenous LEDGF/p75 as well as inhibiting the for-
mation of the SSC by stabilizing incorrect IN multimers
[13], was able to potently inhibit HIV-1 replication
[17,29]. These studies have established the importance
and molecular basis of the interaction of HIV-1 IN with
LEDGF/p75 and have highlighted the primary LEDGF/
p75 binding pocket at the IN CCD-CCD dimer interface
for anti-HIV-1 drug development.
Multifunctional allosteric IN inhibitors (ALLINIs) have
been discovered that potently inhibit HIV-1 replication
(reviewed in [30-33]). These compounds were identified
through two separate methods, including a high through-
put screen for 3’-processing inhibitors or through the
rational design of inhibitors that block the IN-LEDGF/p75
interaction [33-36]. ALLINIs bind to HIV-1 IN in the
principal LEDGF/p75 binding pocket and bridge between
two IN subunits [36-42]. ALLINIs share several common
structural features including a central quinoline ring and
the carboxylic acid moiety on a modifiable one-carbon
linker attached to position 3 of the central ring. Similar to
LEDGF/p75 residue Asp366, the ALLINI carboxylic acid
forms hydrogen bonds with Glu170 and His171 backbone
amides of one IN subunit. Additionally, the quinoline ring
extends to form hydrophobic contacts with the second IN
subunit akin to LEDGF/p75 residue Leu368. However,
unlike LEDGF/p75, potent ALLINIs also contain a tert-
butoxy ether oxygen at the modifiable carbon, which
forms an additional hydrogen bond with the side chain
of IN residue Thr174 [36,37,39,40].
ALLINIs inhibited both IN-LEDGF/p75 binding and
LEDGF/p75 independent assembly of functional SSCs
in vitro [36,37,40,43]. The latter inhibitory activity has
been attributed to the ability of ALLINIs to prematurely
stabilize interacting IN subunits and promote aberrant
higher order protein multimerization [37,40,43]. Con-
sistent with these observations, in infected cells ALLINIs
impaired a step at or prior to 3’-processing and could
reduce LEDGF/p75 mediated integration into active
transcription units [40,44]. Unexpectedly though, the
primary activity of ALLINIs occurs during the late stage
of HIV-1 replication [39,41,42,45,46]. Virions produced in
the presence of ALLINIs exhibited an eccentric morph-
ology characterized by the electron dense material being
mislocalized outside of the capsid core and were further-
more defective for reverse transcription during the subse-
quent round of infection [39,45,46]. This phenotype is
similar to the one caused by certain HIV-1 IN mutations,
which are typed as class II, suggesting that IN structure
may play a yet unidentified role during HIV-1 maturation
[12,39,47-51]. Potential contributions of LEDGF/p75 and
its interactions with IN during the late stage of HIV-1 rep-
lication are unlikely due to the observations that fully
infectious virus particles were formed in LEDGF/p75 KO
or knockdown cells [27,39,45]. Consistent with this view,
LEDGF/p75 over expression did not affect ALLINI poten-
cies in virus producer cells [45]. Instead, ALLINI induced
aberrant IN multimerization has been shown to correlate
with the inhibition of correct particle assembly. Further
support for this notion has been provided by the recent
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MINIs. These compounds are not effective inhibitors of
IN-LEDGF/p75 binding and instead potently induce aber-
rant IN multimerization during virus particle production
and result in eccentric, non-infectious particles [44].
Genotyping HIV-1 in cell culture under the selective
pressure of the archetypal ALLINI BI-1001 and its several
analogs have identified substitutions in the IN coding
sequence near the inhibitor binding sites [36,40,52]. Of
these, the A128T IN substitution was the most prevalent
mutation with HIV-1NL4-3(A128T IN) displaying marked
resistance to respective ALLINI compounds [36,38,40,52].
Interestingly, crystallographic studies have revealed that
BI-1001 is still able to bind A128T IN CCD by maintaining
all hydrogen bonding interactions, but that the quinoline
ring bridging the two IN subunits was slightly shifted com-
pared with the wild type (WT) protein [38]. Consequently,
BI-1001 was unable to promote aberrant multimerization
of recombinant A128T IN, whereas it maintained its ability
to inhibit IN-LEDGF/p75 binding in vitro [38]. The results
of these studies are consistent with the interpretation that
aberrant IN multimerization rather than IN-LEDGF/p75
binding is the primary target of this inhibitor in infected
cells.
Selection of HIV-1 variants in the presence of ALLINI
BI-D (Additional file 1: Figure S1), a more potent analog
of BI-1001, did not result in the A128T mutation but
instead revealed several amino acid changes near the
inhibitor binding sites including Y99H, L102F, A/T124D,
and H171T [52]. Of these, HIV-1 bearing the single
amino acid H171T substitution was found to be one of
the most prominent mutations persisting at the highest
concentration of BI-D tested [52]. Here, we have investi-
gated the mechanism of resistance for the H171T IN
mutation. Our findings show that unlike A128T, the
H171T IN substitution causes resistance to BI-D by
reducing the binding affinity of the inhibitor to IN.
Our structural studies have elucidated a previously
undescribed role of the His171 side chain for hydrogen
bonding with BI-D tert-butoxy ether oxygen, which is com-
promised upon the H171T substitution. Since LEDGF/p75
lacks a tert-butoxy moiety, the H171Tsubstitution has min-
imal effects on IN-LEDGF/p75 binding and accordingly,
HIV-1NL4-3(H171T IN), replicated in cells at WT levels. These
findings have uncovered the structural and mechanistic
basis for H171T IN resistance to BI-D and are expected
to facilitate in the development of second generation
ALLINIs with increased potency and decreased potential
to evolve drug resistance.
Results
To assess the functional significance of the H171T
IN substitution we introduced the mutation into both
HIV-1NL4.3 and recombinant IN. As indicated in Figure 1A
and B, the H171T IN substitution did not significantly
alter virus release from transfected cells as measured by
p24 production or affect the infectivity of the mutant
virus. We next examined the biochemical properties of
purified recombinant H171T IN. Size exclusion chroma-
tography (SEC) experiments revealed that WTand H171T
INs similarly formed tetramers and monomers (Figure 1C).
In a homogeneous time-resolved fluorescence-based (HTRF)
IN activity assay [38], the mutant IN protein exhibited
near WT levels of catalytic function in the absence of
LEDGF/p75 (Figure 1D). Furthermore, LEDGF/p75 was
able to stimulate the strand transfer activity of mutant IN
similarly to WT IN (Figure 1E). This suggested that even
though the H171T IN substitution is within the IN-
LEDGF/p75 binding pocket, IN retains the ability to
effectively bind LEDGF/p75 in vitro and during virus
infection. To test this directly, we compared LEDGF/p75
binding to WT and H171T INs utilizing a HTRF-based
binding assay [38]. WT IN bound LEDGF/p75 with a Kd
of 3.3±0.3 nM, whereas H171T IN bound LEDGF/p75
with a Kd of ~10.5±0.3 nM, a 3.2-fold decrease in affinity
(Figure 1F).
Although the inhibition of particle maturation deter-
mines BI-D potency, the inhibitor displays a second,
substantially weaker activity during the early phase of
HIV-1 replication ([39], Table 1). To gain insight into
the mechanism of BI-D action and the mode of H171T
resistance, HIV-1NL4-3(H171T IN) was evaluated during
both the early and late stages of the replication lifecycle.
When drug exposure was limited to the acute phase of
infection, BI-D EC50 values increased from 1.17 μM for
VSV-G pseudotyped HIV-1NL4-3 to 12.4 μM for the
VSV-G pseudotyped HIV-1NL4-3(H171T IN), ~11-fold re-
sistance (Table 1). However, the H171T IN substitution
resulted in significantly higher levels of resistance
(~68-fold) when drug exposure was limited to the late
stage of replication. To examine the apparent differences
in resistance levels between the early and late stages of
replication, anti-viral potencies of BI-D were determined
in LEDGF/p75 KO cells. The complete removal of en-
dogenous LEDGF/p75 increased BI-D potency during the
acute phase of HIV-1NL4-3 infection, but had minimal effect
on the inhibitor activity when exposure was limited to the
late stage. These results are consistent with other studies
and indicate that during the early stage of replication,
LEDGF/p75 is able to compete with ALLINIs for binding
to IN and hence reduce inhibitor potency [39,53]. However,
LEDGF/p75 expression levels did not detectably alter
ALLINI potencies during the late stage of viral replication
([27,39,41,42,45,46], also see Table 1). The virus containing
the H171T IN substitution still conferred resistance to
BI-D in the absence of endogenous LEDGF/p75, with
28- and 45-fold resistance observed in the KO cells during
the early and late stages, respectively.
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of BI-D display eccentric core morphology, where the
electron dense material normally situated within the
conical core is mislocalized adjacent to a translucent
capsid core and the viral membrane [39]. Consistent
with these findings, when WT HIV-1NL4-3 virions were
produced in the presence of 0.18 μM BI-D (a dose
equivalent to 2×EC50; Table 1), 77% of the virions
Figure 1 Effects of the H171T IN substitution on HIV-1 replication and recombinant IN activities. (A) p24 production of HIV-1NL4-3 and
HIV-1NL4-3(H171T IN) plotted as percent WT with standard deviations shown for n= 3 independent experiments. (B) Single round infection of
HIV-1NL4-3 and HIV-1NL4-3(H171T IN) determined by luciferase expression and plotted as percent WT infectivity with standard deviations shown for
three independent experiments. (C) SEC of WT and H171T INs. The peaks corresponding to tetrameric (T) and monomeric (M) forms of IN are
indicated. (D) HTRF-based LEDGF/p75 independent integration assay and (E) HTRF-based LEDGF/p75 dependent integration assays showing
stimulation of WT and H171T IN activities at indicated LEDGF/p75 concentrations. Total HTRF signal is plotted with standard deviation for three
independent experiments shown. (F) HTRF-based assays to determine LEDGF/p75 binding affinities for WT (opened boxes) or H171T
(closed circles) INs. Error bars indicate standard deviation for three independent experiments.
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at the same concentration of BI-D the H171T IN mutant
virus resulted in only 27% of the virions with eccentric
core morphologies (Figure 2). When BI-D concentrations
were increased to 12 μM, which corresponds to 2×EC50
for HIV-1NL4-3 bearing the H171T IN substitution, the ec-
centric virion morphology for the mutant virus increased
to 82% (Figure 2).
We next wished to dissect the mechanism of the
HIV-1NL4-3(H171T IN) resistance to BI-D. Surface plasmon
resonance (SPR) was used to compare BI-D binding to
recombinant WTand H171T IN CCD proteins. Figure 3
shows that BI-D bound WT IN CCD with a Kd of
0.123 μM, which is in good agreement with the antiviral
activities of BI-D measured in cell culture (Table 1). BI-D
binding to H171T IN CCD resulted in a significantly
higher Kd of 10.3 μM. Significantly, the observed ~84-
fold decrease in the binding affinity of BI-D to the
mutant IN CCD (Figure 3) roughly correlated with
the ~68-fold decrease in the EC50 value seen for antiviral
activity against HIV-1NL4-3 bearing the H171T IN substi-
tution (Table 1).
Previous studies have indicated that the primary mech-
anism of action of ALLINIs is through the promotion of
aberrant IN multimerization [38-41,43]. Therefore, we
compared the effects of BI-D on aberrant multimerization
of WT and H171T INs using dynamic light scattering
(DLS). In the absence of inhibitor (DMSO control), peaks
for soluble WT or mutant IN were not observed by this
technique (Figure 4). Instead, a background signal corre-
sponding to <1 nm diameter was detected both in the
presence of IN and in the buffer alone sample, indicating
that the reaction buffer contained small size particles. For
inhibitor experiments, we examined two concentrations of
BI-D: one (~0.120 μM) that correlated to the Kd value of
the inhibitor binding to WT IN CCD (~0.123 μM) and
the other (10 μM) that correlated with the Kd value for
inhibitor binding to H171T IN CCD (~10.3 μM). Incuba-
tion of 0.12 μMB I - Dw i t hW TI Nf o r1 5m i nr e s u l t e di na
peak corresponding to particles with a diameter of 51 nm,
which significantly exceeds an estimated diameter of
7.5 nm for the IN tetramer in the SSC [54]. The size of
the oligomer continued to increase further to 106 nm and
142 nm diameter at 20 and 30 minutes, respectively
Table 1 Effects of the H171T IN substitution on antiviral activities of BI-D
Producer cells Target cells LEDGF KO producer cells LEDGF KO target cells
EC50 (μM) Fold change EC50 (μM) Fold change EC50 (μM) Fold change EC50 (μM) Fold change
WT IN 0.090± 0.031
a – 1.17±0.1
a – 0.080±0.01 – 0.067±0.02 –
H171T IN 6.11±0.63 67.9x 12.4±0.85 10.6x 2.20± 0.64 28x 2.98± 0.7 44.5x
Means ± S.D. are shown for at least 3 independent experiments.
aData from Ref [39].
Figure 2 Concentration dependent effects of BI-D on viral core morphology for HIV-1NL4-3 and HIV-1NL4-3(H171T IN). (A) Representative
images of mature, eccentric and immature virion morphologies as visualized by electron microscopy. (B) Quantitation of counted virions (100 for
WT or H171T per experiment). Virions were produced in the presence of DMSO, 0.18 μM BI-D or 12.2 μM BI-D as indicated. Graphed are averages
and standard deviation for n= 2 independent experiments.
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(0.12 μM) failed to elicit higher order H171T IN oligomers
even after 30 min incubation (Figure 4B). However, when
the concentration of BI-D was increased to 10 μM, higher
order oligomerization of H171T IN was detected in a time
dependent manner (Figure 4D). As expected, 10 μMB I - D
also induced higher order oligomers of WT IN (Figure 4C).
This suggests that at lower concentrations, BI-D is unable
Figure 3 SPR analysis of BI-D interactions with WT and H171T mutant IN CCDs. SPR binding kinetics for BI-D interactions with (A) WT IN
CCD and (B) H171T IN CCD at indicated inhibitor concentrations. Binding affinities are summarized in C.
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likely due to the decreased affinity of the inhibitor binding
to the mutant protein (Figure 3). However, under condi-
tions of increased inhibitor, BI-D is able to bind H171T
IN (Figure 3) and promote aberrant IN multimerization
(Figure 4D). This indicates that the H171T IN substitution
confers resistance to BI-D by decreasing inhibitor binding
affinity and hence correspondingly decreasing aberrant IN
multimerization.
To understand the structural basis for the reduced
binding affinity of BI-D to H171T IN, we solved the
crystal structure of BI-D in complex with H171T CCD
dimer (Figure 5A) and compared it to the complex of
inhibitor bound to WT CCD dimer ([39], also see
Figure 5B). As expected (Figure 3) with the high concen-
tration of BI-D (~5 mM) used in the crystallographic ex-
periments, the inhibitor bound to H171T CCD dimers.
Furthermore, the H171T substitution did not detectably
affect the inhibitor position within the binding pocket
(compare Figure 5A and B). BI-D hydrophobic interac-
tions with IN CCD subunit 2 as well as hydrogen bonding
between the inhibitor carboxylic acid, and backbone
amides of subunit 1 were fully preserved in both crystal
structures. Furthermore, the Thr174 side chain similarly
hydrogen bonded to the tert-butoxy ester oxygen in
both the WTand mutant IN structures.
Importantly, though, we observed differential interac-
tions of His171 and Thr171 side chains with the inhibitor.
The imidazole group of His171 formed both an electro-
static interaction with the carboxylic acid and a hydrogen
bond with the tert-butoxy oxygen of BI-D (Figure 5B).
However, the side chain of Thr171 which establishes a
novel hydrogen bond with the carboxylic acid was unable
to form a hydrogen bond with the tert-butoxy moiety of
BI-D (compare Figure 5A and B).
To understand how these structural differences con-
tributed to the markedly reduced ability of the inhibitor
to bind H171T IN, we performed absolute binding free
energy calculations for the interactions between WT and
H171T IN CCD dimers with BI-D (Table 2 and Additional
file 1: Figure S2). Nδ-, Nε-a n dd o u b l y( N δ-a n dN ε-)
protonated forms of His171 were considered in our cal-
culations. Table 2 shows that the doubly-protonated
form of His171 and the Nδ-protonated form of His171
have similar calculated ΔGbind (cal) of -11.2 kcal/mol
and -10.1 kcal/mol respectively; whereas a significantly
Figure 4 DLS analysis of BI-D induced oligomerization of recombinant WT and the H171T INs. Shown are the size distributions (%) of IN
after DMSO treatment (blue) or BI-D treatment after 15 minutes (red), 20 minutes (green) and 30 minutes (yellow) incubation. BI-D treatments
include (A) WT IN +0.120 μM BI-D, (B) H171T IN +0.120 μM BI-D, (C) WT IN +10 μM BI-D and (D) H171T IN +10 μM BI-D. The peak with the
diameter size of <1 nm detected in these samples has also been observed for the buffer alone sample indicating that small size particles
unrelated to IN or BI-D were present in our preparations.
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the Nε-protonated form of His171. The calculated ΔGbind
(cal) for the IN containing Thr171 was -6.7 kcal/mol
(Table 2). For comparison, Table 2 also shows the ΔGbind
(exp) values determined using experimental Kd values for
BI-D binding to WT and H171T IN CCDs (Figure 3).
Comparison of ΔGbind (cal) and ΔGbind (exp) suggests that
BI-D binding to WT IN preferentially stabilizes the doubly
protonated form and/or the Nδ-protonated tautomer states
of His171, while the Nε-protonated tautomer is a relatively
minor species in the inhibitor-bound complex. We also
decomposed the computed binding free energy ΔGbind
(cal) into contributions from electrostatic and non-polar
interactions. We compared the results for both BI-D
Figure 5 Crystal structures of BI-D bound to WT and H171T CCD dimers. Panel A is the H171T CCD dimer and panel B is the WT CCD
dimer. BI-D is colored green and individual IN subunits are colored yellow and cyan. Oxygen atoms are shown in red and nitrogen atoms are in
blue. Black dash-lines indicate hydrogen bonding interactions, whereas the magenta dash-line shows the electrostatic interaction between the
protonated Nδ- on His171 and the carboxylic acid of BI-D. The arrow indicates the hydrogen bond between the protonated Nδ- on His171 and
the ether oxygen on the tert-butoxy (B), which is absent in the H171T IN CCD structure (A).
Table 2 Binding free energy calculations for BI-D
interactions with WT and the H171T mutant IN CCDs
Receptor ΔGbind (cal) ΔGbind (exp)
WT IN (His171-doubly-protonated) -11.2 -9.5
WT IN (His171-Nδ-protonated) -10.1
WT IN (His171-Nε-protonated) -5.9
His171T IN -6.7 -6.8
Unit: kcal/mol. ΔGbind (cal) represent calculated values for BI-D binding to
His171 containing either Nδ-, Nε- or doubly protonated tautomer states and
H171T IN CCDs. ΔGbind (exp) values have been calculated based on the
experimental data.
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(data not shown), which suggests that the less favorable
electrostatic interactions between BI-D and Thr171 pri-
marily contribute to the lower Kd value for the inhibitor
binding to the mutant protein. Significantly, comparisons
between the molecular dynamics (MD) simulated struc-
tures obtained with different protonation states of His171
and the crystal structure of BI-D in complex with the WT
IN CCD dimer are consistent with the trend in the com-
puted binding free energies (see Additional file 1: Table S1
and Figure S2).
The simulations also revealed the importance of
hydrogen bonding interactions between the ether oxygen
on the tert-butoxy moiety on BI-D and the protonated
Nδ- on His171. In contrast, to the mutant IN CCD, the
hydroxyl group of the Thr171 side chain does not form
such interactions with the ether oxygen on the inhibitor
(Figure 5). This result is supported by the published
observations that ALLINIs which contain an oxygen
ether linkage are considerably more potent inhibitors
of HIV-1NL4.3 with WT IN than those lacking such an
oxygen atom (reviewed in [31]). To further test this no-
tion we have examined the effects of the H171T IN
substitution on the antiviral activities of LEDGIN-6,
which lacks the tert-butoxy group ([36,37], also see
Additional file 1: Figure S1). LEDGIN-6 was only ~3.4-
fold less potent with respect to HIV-1NL4.3 (H171T IN) (EC50
of 41.4±6.4 μM) (data not shown) versus WT HIV-1NL4.3
(EC50 of 12.2±2.9 μM) [37]. For comparison, BI-D, which
unlike LEDGIN-6 contains the tert-butoxy group, was sig-
nificantly more sensitive (~68-fold, Table 1) to the H171T
IN substitution in HIV-1NL4.3 likely due to the disruption
of the hydrogen bonding between the tert-butoxy ether
oxygen and Nδ-protonated His171.
Next, we wanted to understand the structural basis as
to why the H171T substitution had significantly less
effect on LEDGF/p75 binding (~3.2-fold) compared
with BI-D binding (~84-fold) to recombinant HIV-1
IN. Comparison of available crystal structures of BI-D
or LEDGF/IBD bound to WT HIV-1 IN CCDs [20,39]
revealed that the hydrogen bonding between the pro-
tonated Nδ on His171 and the tert-butoxy ether oxygen
of BI-D is unique to the inhibitor because LEDGF/IBD
does not similarly contact IN. To examine LEDGF/IBD
interactions with the mutant IN we simulated the H171T
change in the available crystal structure [20], which
revealed that unlike BI-D, LEDGF/IBD made the same
number of hydrogen bonds with WT and H171T mutant
INs (Additional file 1: Figure S3). In particular, LEDGF/
p75 D366 can hydrogen bond with the side chain of
Thr171 replacing the lost electrostatic interaction that
occurred with His171. To further test these observations,
we performed relative binding free energy calculations for
LEDGF/IBD binding to WT and H171T IN CCDs. Free
energy perturbation analysis allowed us to calculate that
ΔΔGb=ΔGb(H171T)−ΔGb(WT)=1.08kcal/mol. Since
Kd=e
ΔGb/RT,
Kd H171T ðÞ
Kd WT ðÞ ¼ e ΔGb H171T ðÞ −ΔGb WT ðÞ ½  =RT ¼ eΔΔGb=RT,
the calculated ΔΔGbof 1.08 kcal/mol translates into a rela-
tive binding affinity ratio
Kd H171T ðÞ
Kd WT ðÞ ¼ 6:2. Experimentally,
the Kd of LEDGF/p75 binding to wild type and H171T
mutant INs are ~3.3 nM and 10.5 nM respectively, i.e.
Kd H171T ðÞ
Kd WT ðÞ ¼ 3:2, which is in good agreement with the cal-
culated relative affinity ratio of 6.2.
Discussion
Published studies have shown that ALLINIs are anchored
to the IN dimer interface through their key pharmaco-
phore, the carboxylic acid, hydrogen bonding with the
backbone amides of IN residues Glu170 and His171.
Furthermore, the Thr174 side chain has been implicated
in hydrogen bonding with the ALLINI tert-butoxy ether
oxygen [37,38,40]. However, the contributions of the
His171 side chain for interacting with this class of
inhibitors have not been previously elucidated. Yet, geno-
typing of HIV-1NL4-3 variants under increasing selective
pressure of ALLINI BI-D has revealed the H171T IN sub-
stitution as a key amino acid substitution. In addition, this
variant persists at the highest inhibitor concentration
tested suggesting that the amino acid side chain change
at position 171 contributes to the evolved resistance to
BI-D [52]. The present studies provide mechanistic and
structural clues for these observations. We show that
HIV-1NL4-3 containing the H171T IN substitution con-
fers ~68-fold resistance to BI-D. Significantly, this level
of resistance in infected cells correlates closely with ~84-
fold reduced binding affinity of the inhibitor to recom-
binant H171T IN CCD as compared with its WTcoun-
terpart. Crystallographic experiments and binding free
energy calculations have indicated that Nδ-protonated
or doubly protonated forms of the imidazole ring of
His171 can engage in both electrostatic interactions
with BI-D carboxylic acid as well as hydrogen bonding
with the tert-butoxy ether oxygen of the inhibitor.
These interactions are compromised by the H171T
substitution, with the Thr171 side chain forming a less
electrostatically favorable hydrogen bond with the BI-D
carboxylic acid and lacking any additional interactions
with the tert-butoxy ether oxygen (Figure 5).
In contrast with the significant reduction in BI-D bind-
ing affinity, the H171T IN substitution only minimally re-
duced LEDGF/p75 binding affinity to recombinant H171T
IN. In infected cells, where endogenous LEDGF/p75 levels
significantly exceed what is needed for HIV-1 integration,
HIV-1NL4-3 with the H171T substitution was not compro-
mised for HIV-1 replication. The MD simulations and
binding free energy calculation have revealed important
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binding to HIV-1 IN. The Nδ protonated His171 hydrogen
bonds the tert-butoxy ether oxygen of BI-D, which is com-
promised upon the H171T IN substitution. In contrast,
such interactions are not formed between WT IN and
LEDGF/IBD. Accordingly, the H171T IN change minimally
affects the IN-LEDGF/p75 binding. Furthermore, unlike
BI-D which engages only a small pocket at the CCD-CCD
dimer interface, LEDGF/p75 establishes additional exten-
sive interactions with HIV-1 IN, which extend beyond the
CCD-CCD dimer interface and include strong electrostatic
interactions between positively charged residues along
LEDGF/IBD α- h e l i x4a n dan u m b e ro fa c i d i cr e s i d u e so f
α-helix 1 of IN [26]. HIV-1 seems to exploit these structural
differences between BI-D and LEDGF/p75 interactions with
IN during the process of evolution of the H171T IN escape
mutation.
The mechanism for H171T IN resistance is distinct
from the previously described mechanism of resistance
for the A128T IN escape mutation under the selective
pressure of related, archetypal inhibitor BI-1001 [38].
The A128T IN substitution does not significantly reduce
BI-1001 binding to HIV-1 IN CCD with all hydrogen
bonding and electrostatic interactions of BI-1001 with
HIV-1 IN being fully preserved in WT and A128T INs.
Instead, the substitution of Ala with bulkier and polar
Thr repositioned BI-1001 at the IN CCD dimer interface
and reduced its ability to effectively bridge between two
IN subunits. Consequently, bound BI-1001 failed to in-
duce aberrant multimerization of recombinant A128T IN
and accordingly HIV-1NL4-3 containing the A128T IN sub-
stitution exhibited marked resistance to BI-1001 [38]. In
contrast, the H171T IN substitution was able to resist BI-
D through decreasing the ability of the inhibitor to bind
IN. However, at high BI-D concentrations, BI-D is able to
bind, effectively bridging two IN subunits, and inducing
aberrant IN multimerization. Collectively these findings
provide important structural and mechanistic details for a
novel mechanism of resistance.
Analysis of our crystal structure of BI-D bound to
HIV-1 IN CCDs has revealed 13 residues (Gln95, Tyr99,
Leu102, Thr124, Thr125, Trp132, Ala128, Ala129, Ala169,
Glu170, His171, Lys173 and Met178) that are within 5 Å
of the inhibitor. Of these only IN amino acids 124 and 125
are polymorphic withThr predominating at both positions
in clade B, whereas the majority of clade C strains contain
Ala124 and Ala125 [55]. Recent studies [33] have shown
that these polymorphic substitutions only modestly affected
the antiviral potencies of various ALLINIs. We also note
close structural similarity between BI-D and BI-224436, the
first ALLINI to advance into phase 1a clinical trials ([33],
also see Additional file 1: Figure S3). These two compounds
exhibit similar antiviral activities in cell culture with an
EC50 range of 51-90 nM for BI-D and 11-27 nM for BI-
224436 with respect to different viral strains [33,39,56].
However, the latter compound has been chosen for
clinical trials due to its excellent pharmacokinetic pro-
file in rats [33]. These two compounds differ only in
the substituted ring system, with BI-D and BI-224436
containing bicyclic and tricyclic arenes, respectively
([33], also see Additional file 1: Figure S3). While the
crystal structure for BI-224436 bound to HIV-1 IN CCDs
has not been published, based on its close structural
similarity with BI-D we predict that both bi- and tricyclic
arenes would similarly dock in the hydrophobic pocket
that encompasses Leu102, Ala128, Ala129, Trp132 and
Met178. At the same time the key interactions between
the Nδ- protonated imidazole group of His171 with the
tert-butoxy ether oxygen and electrostatic interactions
with the inhibitor carboxylic acid are likely to be equally
important for both BI-D and BI-224436 binding to HIV-1
IN. Therefore, our findings are expected to facilitate in the
development of improved IN inhibitors for potential clin-
ical use.
Conclusions
We have elucidated a distinct mechanism of resistance
for the H171T IN mutation to the potent ALLINI BI-D.
Our findings indicate the importance of the His171 side
chain for binding the inhibitor and that its substitution
to Thr171 markedly reduces the binding affinity and
corresponding inhibitory activity of BI-D.
Methods
Antiviral compounds, plasmids, and DNA constructs
BI-D and LEDGIN-6 were synthesized as previously de-
scribed [37,53]. Plasmid pNL4.3/Xmal [57] encodes for
replication competent HIV-1NL4-3. Plasmids pNLX.Luc.R
-
[58] or pNL4-3.Luc.Env- [59] encodes for single-round
HIV-1NL4-3 carrying the luciferase reporter gene. Vesicular
stomatitis virus G glycoprotein was encoded by pCG-
VSV-G [57]. The H171T substitution was introduced into
the IN coding region of pNLX.Luc.R-, pNL4-3.Luc.Env-
and pNL4-3/Xmal using PCR-site directed mutagenesis
(Agilent) and verified by dideoxy sequencing.
Cells, viruses and antiviral assays
Parental HEK293T and HEK293T LEDGF/p75 KO cells
[60] were grown in Dulbecco’s modified Eagle medium
(Invitrogen) supplemented with 10% (vol/vol) fetal bovine
serum (FBS) (Invitrogen), 100 IU/mL penicillin, and
100 μg/mL streptomycin (Gibco). SupT1 cells were
maintained in RPMI medium 1640 containing 10% FBS,
100 IU/mL penicillin and 100 μg/mL streptomycin.
HIV-Luc was pseudotyped by cotransfecting HEK293T
cells with either pNLX.Luc.R- or pNL4-3.Luc.Env- and
with pCG-VSV-G using PolyJet DNA transfection reagent
(SignaGen Laboratories).
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DMSO or the inhibitor was added at indicated concentra-
tions during media exchange at 18-20 hrs post-transfection.
Cell-free supernatants were measured for p24 content util-
izing a commercial p24 ELISA kit (Advanced Biosciences
Laboratories). SupT1 cells were infected in triplicate
with HIV-Luc normalized for p24 content (5 ng/mL
p24). Luciferase values were determined 48 hrs post-
infection.
To assess antiviral activity during the early stage of
HIV-1 replication, DMSO or the inhibitor was added at
the indicated concentrations to the target cells 30 min
before or at the time of infection. Luciferase values,
expressed as relative light units were determined 48 hrs
post-infection.
Electron microscopy
Cell-free HIV-1NL4-3 from transfected HEK293T cell su-
pernatants was concentrated via ultracentrifugation at 4°C
for 2 hrs in a Beckman SW41 rotor at 32,000 rpm prior to
fixation in 2% paraformaldehyde and submission to the
Harvard Medical School Electron Microscopy core facility.
Images were taken with a JEOL 1200EX microscope
equipped with an AMT 2 k charge-coupled device
camera. Virus particles (100 per experimental sample)
were counted by eye.
Expression and purification of recombinant proteins
WT HIV-1 IN, H171T HIV-1 IN and LEDGF/p75 recom-
binant proteins with 6xHis or FLAG tags were expressed
in E. coli and purified as described previously [37]. WT
and H171T HIV-1 IN CCD (residues 50-212) containing
the F185K mutation were expressed in E. coli and purified
as described [37].
Crystallization and X-ray crystal structure determination
Recombinant H171T IN CCD (50-212) containing the
F185K solubilizing substitution was prepared to ~8 mg/ml
and grown at 4°C using hanging drop vapor diffusion
method. The crystallization buffer contains 8% PEG 8 K,
0.1 M Na cacodylate, pH 6.5, 0.1 M ammonium sulfate
and 5 mM DTT. Protein (1 μl) was mixed with the equal
volume of the crystallization buffer. Within 4 weeks the
cubic shape crystals reached 0.1- 0.2 mm in size. The
soaking buffer containing 5 mM BI-D was prepared by
dissolving the compound in crystallization buffer supple-
mented with 10% DMSO. The protein crystal was soaked
in the buffer for 12 hrs at 4°C before it was flash-frozen
with liquid nitrogen. Diffraction data from the crystals
were collected at 100 F on a Rigaku Raxis 4++ image plate
detector in OSU Crystallography Facility. The intensity
data integration and reduction were performed with
HKL2000 program [61]. Molecular Replacement program
Phaser [62] in CCP4 package method was used to solve
the structure. Coot [63] was used for the subsequent
refinement and building of the structure. Refmac5 [64] of
the CCP4 package was used for the restraint refinement.
The crystal belong to space group P3121 with cell dimen-
sions of a=b =72.2 Å, c =66 Å; One 18 kDa monomer
resides in the asymmetric unit. The structure was refined
to 1.94 Å with Rcryst/Rfree =0.190/0.221. Coordinates have
been deposited in the Protein Data Bank with accession
number 4TSX (Additional file 1: Table S2).
Binding free energy calculations
The absolute binding free energies between the various
forms of IN CCD dimer and BI-D were calculated using
the double decoupling method (DDM) [65-68] in explicit
solvent (TIP3P water model [69] plus counterions) at
300 K. The protein molecules are modeled by the Amber
ff99sb-ILDN force field [70], and the ligand BI-D is
described by the Amber GAFF [71] parameters set. The
partial charges of the ligands are obtained using the
AM1-BCC method [72]. A DDM calculation involves
two legs of simulation, in which a restrained ligand is
gradually decoupled from the receptor binding pocket or
from the aqueous solution. In each leg of the decoupling
simulations, the Coulomb interaction is turned off first
using 11 lambda windows, and the Lennard-Jones interac-
tions are then turned off in 17 lambda windows. The two
decoupling free energies ΔG
gas*→complex and ΔG
gas→water
associated with the two legs of the DDM cycle were de-
termined using thermodynamic integration (TI). The
Hamiltonian derivative 〈∂U/∂λ〉λ at a series of l from 0
to 1 were collected and integrated to obtain the free en-
ergy difference. For absolute binding free energy calcula-
tions, the MD simulation at each λ was performed using
the GROMACS [73,74] version 4.6.4 for 15 ns; the last
10 ns was used for the calculation of binding free energy.
SEC
A Superdex 200 10/300 GL column (GE Healthcare) was
used to analyze multimeric forms of recombinant WT
and H171T INs in buffer containing 20 mM HEPES
(pH 6.8), 750 mM NaCl, 10 mM MgSO4, 0.2 mM EDTA,
5 mM BME, 5% glycerol and 200 μMZ n C l 2.T h ef o l -
lowing proteins were used to calibrate the column: bovine
thyroglobulin (670,000 Da), bovine gamma-globulin
(158,000 Da), chicken ovalbumin (44,000 Da), horse
myoglobin (17,000 Da) and vitamin B12 (1,350 Da).
Proteins were detected by absorbance at 280 nm. All
the procedures were performed at 4°C.
DLS
DLS experiments were carried out as previously reported
[44]. Briefly, DMSO, 0.12 μMB I - D ,o r1 0μM BI-D was in-
cubated with 200 nM WT or H171T IN. DLS signals were
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using a Malvern Nano series Zetasizer instrument.
SPR
SPR was performed using a Biacore T100 (GE Healthcare).
A series s sensor chip NTA (GE Healthcare) was condi-
tioned with 0.5 mM NiCl2 at a flow rate of 10 μl/min for
1m i nf o l l o w e db ya1m i nw a s ho f3m ME D T Aa taf l o w
rate of 10 μl/min. WT or H171T 6xHis-CCD 4 μg/mL in
HBS-P, (GE Healthcare) was immobilized on the chip to
4400 response units (RU). Indicated BI-D concentrations in
HBS-P with 10% DMSO was flowed over the cell for 180 s
at a flow rate of 40 μl/min followed by a 5 min dissociation.
The chip was regenerated with 500 mM imidazole.
Catalytic activities of recombinant INs
LEDGF/p75 dependent integration and LEDGF/p75 in-
dependent integration assays were performed using
HTRF-based assays as described [38] with minor modifi-
cations. LEDGF/p75 independent assays were executed
by incubating 400 nM WT or H171T IN with 50 nM
Cy-5 labeled donor DNA and 10 nM biotinylated target
DNA. For LEDGF/p75 dependent integration assays, 100
nM WT or H171T IN was incubated with 50 nM Cy-5
labeled donor, 10 nM biotinylated target DNA and 50
nM or 100 nM LEDGF/p75. After the addition of
europium-streptavidin, the HTRF signal was recorded
using a Perkin Elmer EnSpire multimode plate reader.
HTRF-based assay for IN-LEDGF/p75 interactions
A previously described HTRF-based assay [37] was
modified to monitor LEDGF/p75 binding to WT and
H171T INs. Briefly, C-terminally FLAG-tagged LEDGF/
p75 (0.01 – 100 nM) was titrated in the binding buffer
(25 mM Tris, pH 7.4, 150 mM NaCl, 2 mM MgCl2,0 . 1 %
Nonidet P-40, 1 mg/ml BSA) containing 10 nM N-
terminally 6XHis WT or H171T HIV-1 IN. Anti-6xHis-
XL665 and anti-FLAG-EuCryptate antibodies (Cisbio,
Inc., Bedford, MA) were added to the reaction and the
HTRF signal vs LEDGF/p75 concentration curves were
fitted to Hill Equation to identify the Kd values for IN-
LEDGF/p75 binding.
Additional file
Additional file 1: Structural analysis of the free energy simulations of
BI-D binding to HIV-1 IN CCD; Table S1. Heavy RMS deviation between
the simulated bound ligand and the crystal structures; Table S2. Data
collection and structure refinement statistics; Figure S1. Chemical structures
of BI-D, LEDGIN-6 and BI-224436; Figure S2. The MD simulated structures
obtained using different His171 protonation states; Figure S3. The MD
simulations reveal similar hydrogen bonding between LEDGF/p75 Asp366
with the WT (left) and the H171T mutant (right) IN CCDs.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MK, AE, RML, EP and JRF designed the study. AS, KJ, LF, JJK and RCL carried
out the experiments. ND performed binding free energy calculations. HF,
PAP, and NJ provided reagents. AS and MK wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgments
We thank Dr. Dennis Bong (OSU, Chemistry Department) for the use of the
DLS instrument and Dr. Drew Dangel for technical assistance with SPR
experiments. The present study was supported by the National Institutes of
Health (grants AI062520 to M.K., GM103368 to M.K., A.E., R.M.L. and J.R.F.,
AI039394 to A.E., AI110310 to M.K. and J.R.F., AI110270 to J.J.K., GM30580 to R.
M.L., AI77344 and the John H. Tietze Foundation Trust to E.M.P.).
Author details
1Center for Retrovirus Research and Comprehensive Cancer Center, College
of Pharmacy, The Ohio State University, 496 W. 12th Ave, 508 Riffe Building,
Columbus, OH 43210, USA.
2Department of Cancer Immunology and AIDS,
Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical
School, Boston, MA 02215, USA.
3Department of Chemistry and Center for
Biophysics and Computational Biology, College of Science and Technology,
Temple University, Philadelphia, PA 19122, USA.
4Department of Molecular
Medicine & Division of Infectious Diseases, Mayo Clinic College of Medicine,
Rochester, MN 55905, USA.
5Division of Medicinal Chemistry and
Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus,
OH 43210, USA.
Received: 30 June 2014 Accepted: 24 October 2014
References
1. Brown PO: Integration. In Retroviruses. Edited by Coffin JM, Hughes SH,
Varmus HE. Plainview, NY: Cold Spring Harbor Laboratory; 1997:161–204.
2. Hazuda DJ: HIV integrase as a target for antiretroviral therapy. Curr Opin
HIV AIDS 2012, 7:383–389.
3. Sichtig N, Sierra S, Kaiser R, Daumer M, Reuter S, Schulter E, Altmann A,
Fatkenheuer G, Dittmer U, Pfister H, Esser S: Evolution of raltegravir
resistance during therapy. J Antimicrob Chemother 2009, 64:25–32.
4. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M,
Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A,
Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier
KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD,
Nguyen BY, Teppler H: Raltegravir with optimized background therapy for
resistant HIV-1 infection. N Engl J Med 2008, 359:339–354.
5. Metifiot M, Vandegraaff N, Maddali K, Naumova A, Zhang X, Rhodes D,
Marchand C, Pommier Y: Elvitegravir overcomes resistance to raltegravir
induced by integrase mutation Y143. AIDS 2011, 25:1175–1178.
6. Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA: The
M50I polymorphic substitution in association with the R263K mutation
in HIV-1 subtype B integrase increases drug resistance but does not
restore viral replicative fitness. Retrovirology 2014, 11:7.
7. Li M, Mizuuchi M, Burke TR Jr, Craigie R: Retroviral DNA integration:
reaction pathway and critical intermediates. EMBO J 2006, 25:1295–1304.
8. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P: Retroviral intasome
assembly and inhibition of DNA strand transfer. Nature 2010, 464:232–236.
9. Maertens GN, Hare S, Cherepanov P: The mechanism of retroviral integration
from X-ray structures of its key intermediates. Nature 2010, 468:326–329.
10. Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A:
Structure-based modeling of the functional HIV-1 intasome and its
inhibition. Proc Natl Acad Sci U S A 2010, 107:15910–15915.
11. Kessl JJ, Li M, Ignatov M, Shkriabai N, Eidahl JO, Feng L, Musier-Forsyth K,
Craigie R, Kvaratskhelia M: FRET analysis reveals distinct conformations of
IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res
2011, 39:9009–9022.
12. Johnson BC, Metifiot M, Ferris A, Pommier Y, Hughes SH: A homology
model of HIV-1 integrase and analysis of mutations designed to test the
model. J Mol Biol 2013, 425:2133–2146.
13. McKee CJ, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, Kvaratskhelia M:
Dynamic modulation of HIV-1 integrase structure and function by
cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol
Chem 2008, 283:31802–31812.
Slaughter et al. Retrovirology 2014, 11:100 Page 12 of 14
http://www.retrovirology.com/content/11/1/10014. Kessl JJ, Eidahl JO, Shkriabai N, Zhao Z, McKee CJ, Hess S, Burke TR Jr,
Kvaratskhelia M: An allosteric mechanism for inhibiting HIV-1 integrase
with a small molecule. Mol Pharmacol 2009, 76:824–832.
15. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J,
Engelborghs Y, De Clercq E, Debyser Z: HIV-1 integrase forms stable
tetramers and associates with LEDGF/p75 protein in human cells. J Biol
Chem 2003, 278:372–381.
16. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR,
Bushman F: A role for LEDGF/p75 in targeting HIV DNA integration. Nat
Med 2005, 11:1287–1289.
17. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W,
Poeschla EM: An essential role for LEDGF/p75 in HIV integration. Science
2006, 314:461–464.
18. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, Kellam P,
Cherepanov P, Engelman A: LEDGF/p75 functions downstream from
preintegration complex formation to effect gene-specific HIV-1
integration. Genes Dev 2007, 21:1767–1778.
19. Busschots K, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, Christ F,
Debyser Z: The interaction of LEDGF/p75 with integrase is lentivirus-
specific and promotes DNA binding. J Biol Chem 2005, 280:17841–17847.
20. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A: Structural
basis for the recognition between HIV-1 integrase and transcriptional
coactivator p75. Proc Natl Acad Sci U S A 2005, 102:17308–17313.
21. Eidahl JO, Crowe BL, North JA, McKee CJ, Shkriabai N, Feng L, Plumb M,
Graham RL, Gorelick RJ, Hess S, Poirier MG, Foster MP, Kvaratskhelia M:
Structural basis for high-affinity binding of LEDGF PWWP to
mononucleosomes. Nucleic Acids Res 2013, 41:3924–3936.
22. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA: Psip1/Ledgf
p52 binds methylated histone H3K36 and splicing factors and
contributes to the regulation of alternative splicing. PLoS Genet 2012,
8:e1002717.
23. van Nuland R, van Schaik FM, Simonis M, van Heesch S, Cuppen E, Boelens
R, Timmers HM, van Ingen H: Nucleosomal DNA binding drives the
recognition of H3K36-methylated nucleosomes by the PSIP1-PWWP
domain. Epigenetics Chromatin 2013, 6:12.
24. Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A:
Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75.
Nat Struct Mol Biol 2005, 12:526–532.
25. Hare S, Di Nunzio F, Labeja A, Wang J, Engelman A, Cherepanov P:
Structural basis for functional tetramerization of lentiviral integrase. PLoS
Pathog 2009, 5:e1000515.
26. Hare S, Shun MC, Gupta SS, Valkov E, Engelman A, Cherepanov P: A novel
co-crystal structure affords the design of gain-of-function lentiviral
integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS
Pathog 2009, 5:e1000259.
27. Fadel HJ, Morrison JH, Saenz DT, Fuchs JR, Kvaratskhelia M, Ekker SC,
Poeschla EM: TALEN knockout of the PSIP1 gene in human cells: analyses
of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol
2014, 88:9704–9717.
28. Marshall HM, Ronen K, Berry C, Llano M, Sutherland H, Saenz D, Bickmore W,
Poeschla E, Bushman FD: Role of PSIP1/LEDGF/p75 in lentiviral infectivity
and integration targeting. PLoS One 2007, 2:e1340.
29. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J,
Vercammen J, Engelborghs Y, Christ F, Debyser Z: Overexpression of the
lens epithelium-derived growth factor/p75 integrase binding domain
inhibits human immunodeficiency virus replication. J Virol 2006,
80:11498–11509.
30. Jurado KA, Engelman A: Multimodal mechanism of action of allosteric
HIV-1 integrase inhibitors. Expert Rev Mol Med 2013, 15:e14.
31. Engelman A, Kessl JJ, Kvaratskhelia M: Allosteric inhibition of HIV-1
integrase activity. Curr Opin Chem Biol 2013, 17:339–345.
32. Demeulemeester J, Chaltin P, Marchand A, De Maeyer M, Debyser Z, Christ
F: LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent
review (2006–2014). Expert Opin Ther Pat 2014, 24:609–632.
33. Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, Pesant M,
Brochu C, Morin S, Chabot C, Halmos T, Bousquet Y, Bailey MD, Kawai SH,
Coulombe R, LaPlante S, Jakalian A, Bhardwaj PK, Wernic D, Schroeder P,
Amad M, Edwards P, Garneau M, Duan J, Cordingley M, Bethell R, Mason
SW, Bös M, Bonneau P, Poupart MA, et al: Discovery of BI 224436, a
Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. ACS Med Chem Lett
2014, 5:422–427.
34. Fenwick C, Lamorte L, Bethell R, Bonneau P, Cordingly M, Coulombe R,
Duan J, Edwards P, Mason S, Poupart M-A, Simoneau B, Tsantrizos Y, Yoakim
C: Discovery of a novel HIV-1 non-catalytic site integrase inhibitor
[abstract]. In 4th International Conference on Retroviral Integration. 047th
edition. Siena: 2011:s5.
35. Tsantrizos YS, Boes M, Brochu C, Fenwick C, Malenfant E, Mason S, Pesant M:
Inhibitors of Human Immunodeficency Virus Repllication. Germany: Boehringer
Ingelheim International GmbH; 2007. WO2007/131350.
36. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D,
Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M,
Chaltin P, Debyser Z: Rational design of small-molecule inhibitors of
the LEDGF/p75-integrase interaction and HIV replication. Nat Chem
Biol 2010, 6:442–448.
37. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu
L, Le Grice SF, Engelman A, Fuchs JR, Kvaratskhelia M: A multimode,
cooperative mechanism of action of allosteric HIV-1 integrase inhibitors.
J Biol Chem 2012, 287:16801–16811.
38. Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel
PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M: The A128T
resistance mutation reveals aberrant protein multimerization as the
primary mechanism of action of allosteric HIV-1 integrase inhibitors.
J Biol Chem 2013, 288:15813–15820.
39. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W,
Ballandras-Colas A, Patel PA, Fuchs JR, Kvaratskhelia M, Engelman A:
Allosteric integrase inhibitor potency is determined through the
inhibition of HIV-1 particle maturation. Proc Natl Acad Sci U S A 2013,
110:8690–8695.
40. Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung
M, Samuel D, Novikov N, Xu Y, Mitchell M, Guo H, Babaoglu K, Liu X,
Geleziunas R, Sakowicz R: New class of HIV-1 integrase (IN) inhibitors with
a dual mode of action. J Biol Chem 2012, 287:21189–21203.
41. Gupta K, Brady T, Dyer BM, Malani N, Hwang Y, Male F, Nolte RT, Wang L,
Velthuisen E, Jeffrey J, Van Duyne GD, Bushman FD: Allosteric inhibition of
human immunodeficiency virus integrase: late block during viral
replication and abnormal multimerization involving specific protein
domains. J Biol Chem 2014, 289:20477–20488.
42. Le Rouzic E, Bonnard D, Chasset S, Bruneau JM, Chevreuil F, Le Strat F,
Nguyen J, Beauvoir R, Amadori C, Brias J, Vomscheid S, Eiler S, Lévy N,
Delelis O, Deprez E, Saïb A, Zamborlini A, Emiliani S, Ruff M, Ledoussal B,
Moreau F, Benarous R: Dual inhibition of HIV-1 replication by integrase-
LEDGF allosteric inhibitors is predominant at the post-integration stage.
Retrovirology 2013, 10:144.
43. Christ F, Shaw S, Demeulemeester J, Desimmie BA, Marchand A, Butler S,
Smets W, Chaltin P, Westby M, Debyser Z, Pickford C: Small-molecule
inhibitors of the LEDGF/p75 binding site of integrase block HIV
replication and modulate integrase multimerization. Antimicrob Agents
Chemother 2012, 56:4365–4374.
44. Sharma A, Slaughter A, Jena N, Feng L, Kessl JJ, Fadel HJ, Malani N, Male F,
Wu L, Poeschla E, Bushman FD, Fuchs JR, Kvaratskhelia M: A new class of
multimerization selective inhibitors of HIV-1 Integrase. PLoS Pathog 2014,
10:e1004171.
45. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, Niedziela-Majka A,
Stray KM, Sakowicz R, Cihlar T: Non-catalytic site HIV-1 integrase inhibitors
disrupt core maturation and induce a reverse transcription block in target
cells. PLoS One 2013, 8:e74163.
46. Desimmie BA, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C,
Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, Hendrix J, Bannert N,
Gijsbers R, Christ F, Debyser Z: LEDGINs inhibit late stage HIV-1 replication
by modulating integrase multimerization in the virions. Retrovirology
2013, 10:57.
47. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R: Multiple
effects of mutations in human immunodeficiency virus type 1 integrase
on viral replication. J Virol 1995, 69:2729–2736.
48. Engelman A: In vivo analysis of retroviral integrase structure and
function. Adv Virus Res 1999, 52:411–426.
49. Engelman A: Pleiotropic nature of HIV-1 integrase mutations. In HIV-1
Integrase: Mechanism and Inhibitor Design. Edited by Neamati N. Hoboken:
John Wiley & Sons; 2011:67–81.
50. Bukovsky A, Gottlinger H: Lack of integrase can markedly affect human
immunodeficiency virus type 1 particle production in the presence of an
active viral protease. J Virol 1996, 70:6820–6825.
Slaughter et al. Retrovirology 2014, 11:100 Page 13 of 14
http://www.retrovirology.com/content/11/1/10051. Cannon PM, Wilson W, Byles E, Kingsman SM, Kingsman AJ: Human
immunodeficiency virus type 1 integrase: effect on viral replication of
mutations at highly conserved residues. J Virol 1994, 68:4768–4775.
52. Fenwick CW, Tremblay S, Wardrop E, Bethell R, Coulomb R, Elston R,
Faucher AM, Mason S, Simoneau B, Tsantrizos Y, Yoakim C: Resistance
studies with HIV-1 non-catalytic site integrase inhibitors [abstract]. Antivir
Ther 2011, 16(Suppl 1):A9.
53. Wang H, Jurado KA, Wu X, Shun MC, Li X, Ferris AL, Smith SJ, Patel PA,
Fuchs JR, Cherepanov P, Kvaratskhelia M, Hughes SH, Engelman A: HRP2
determines the efficiency and specificity of HIV-1 integration in LEDGF/
p75 knockout cells but does not contribute to the antiviral activity of a
potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res 2012,
40:11518–11530.
54. Kotova S, Li M, Dimitriadis EK, Craigie R: Nucleoprotein intermediates in
HIV-1 DNA integration visualized by atomic force microscopy. J Mol Biol
2010, 399:491–500.
55. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW: Natural
variation of HIV-1 group M integrase: implications for a new class of
antiretroviral inhibitors. Retrovirology 2008, 5:74.
56. Fader LD, Carson R, Morin S, Bilodeau F, Chabot C, Halmos T, Bailey MD,
Kawai SH, Coulombe R, Laplante S, Mekhssian K, Jakalian A, Garneau M,
Duan J, Mason SW, Simoneau B, Fenwick C, Tsantrizos Y, Yoakim C:
Minimizing the contribution of enterohepatic recirculation to clearance
in rat for the NCINI class of inhibitors of HIV. ACS Med Chem Lett 2014,
5:711–716.
57. Brown HE, Chen H, Engelman A: Structure-based mutagenesis of the
human immunodeficiency virus type 1 DNA attachment site: effects on
integration and cDNA synthesis. J Virol 1999, 73:9011–9020.
58. Lu R, Limon A, Devroe E, Silver PA, Cherepanov P, Engelman A: Class II
integrase mutants with changes in putative nuclear localization signals
are primarily blocked at a postnuclear entry step of human
immunodeficiency virus type 1 replication. J Virol 2004, 78:12735–12746.
59. Connor RI, Chen BK, Choe S, Landau NR: Vpr is required for efficient
replication of human immunodeficiency virus type-1 in mononuclear
phagocytes. Virology 1995, 206:935–944.
60. Fadel HJ, Morrison J, Saenz D, Ekker SC, Fuchs JR, Kvaratskhelia M, Poeschla
EM: Conference on Retroviruses and Opportunistic Infections; March 3-6.
Boston: IAS-USA/CROI Foundation; 2014:177.
61. Otwinowski Z, Minor W: Processing of X-ray diffraction data collected in
oscillation mode. In Methods in Enzymology, Volume 276. Edited by Carter
CW, Sweet RM. New York: Academic; 1997:307–326.
62. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ:
Phaser crystallographic software. J Appl Crystallogr 2007, 40:658–674.
63. Emsley P, Lohkamp B, Scott WG, Cowtan K: Features and development of
Coot. Acta Crystallogr D Biol Crystallogr 2010, 66:486–501.
64. Murshudov GN, Vagin AA, Dodson EJ: Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr D Biol
Crystallogr 1997, 53:240–255.
65. Gilson MK, Given JA, Bush BL, McCammon JA: The statistical-thermodynamic
basis for computation of binding affinities: a critical review. Biophys J 1997,
72:1047–1069.
66. Boresch S, Tettinger F, Leitgeb M, Karplus M: Absolute binding free
energies: a quantitative approach for their calculation. J Phys Chem B
2003, 107:9535–9551.
67. Wang J, Deng Y, Roux B: Absolute binding free energy calculations using
molecular dynamics simulations with restraining potentials. Biophys J
2006, 91:2798–2814.
68. Deng NJ, Zhang P, Cieplak P, Lai L: Elucidating the energetics of
entropically driven protein-ligand association: calculations of absolute
binding free energy and entropy. J Phys Chem B 2011, 115:11902–11910.
69. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML:
Comparison of simple potential functions for simulating liquid water.
J Chem Phys 1983, 79:926–935.
70. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, Shaw
DE: Improved side-chain torsion potentials for the Amber ff99SB protein
force field. Proteins 2010, 78:1950–1958.
71. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA: Development and
testing of a general amber force field. J Comput Chem 2004,
25:1157–1174.
72. Jakalian A, Jack DB, Bayly CI: Fast, efficient generation of high-quality
atomic charges. AM1-BCC model: II. Parameterization and validation.
J Comput Chem 2002, 23:1623–1641.
73. Hess B, Kutzner C, Van Der Spoel D, Lindahl E: GROMACS 4: algorithms for
highly efficient, load-balanced, and scalable molecular simulation.
J Chem Theor Comput 2008, 4:435–447.
74. Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith
JC, Kasson PM, van der Spoel D, Hess B, Lindahl E: GROMACS 4.5: a
high-throughput and highly parallel open source molecular simulation
toolkit. Bioinformatics (Oxford, England) 2013, 29:845–854.
doi:10.1186/s12977-014-0100-1
Cite this article as: Slaughter et al.: The mechanism of H171T resistance
reveals the importance of Nδ-protonated His171 for the binding of
allosteric inhibitor BI-D to HIV-1 integrase. Retrovirology 2014 11:100.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Slaughter et al. Retrovirology 2014, 11:100 Page 14 of 14
http://www.retrovirology.com/content/11/1/100